Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials

Pedro L Gonzalez, Urania Rappo, Karthik Akinapelli, Jennifer S McGregor, Sailaja Puttagunta, Michael W Dunne, Pedro L Gonzalez, Urania Rappo, Karthik Akinapelli, Jennifer S McGregor, Sailaja Puttagunta, Michael W Dunne

Abstract

Introduction: Dalbavancin is a long-acting, bactericidal, lipoglycopeptide antibiotic approved by the US Food and Drug Administration and the European Medicines Agency for treatment of acute bacterial skin and skin structure infections in adults, with potent activity against Gram-positive pathogens, including methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Here we describe the clearance and clinical outcomes of patients with S. aureus bacteremia in five clinical trials of skin and skin structure infections or catheter-related bloodstream infections that evaluated the efficacy and safety of dalbavancin.

Methods: Patients with uncomplicated S. aureus bacteremia identified in blood cultures drawn at baseline (before study drug) with at least one follow-up blood culture are described from four phase 3 trials in skin and skin structure infections and one phase 2 catheter-related infection study. Dalbavancin was administered as a single-dose (1500 mg intravenous [IV]) or a two-dose regimen (1000 mg IV on day 1, 500 mg IV on day 8). Comparators included vancomycin IV or linezolid IV/oral for 10-14 days.

Results: All 39 patients (100%) who received dalbavancin, including 8 patients on the single-dose regimen, had clearance of bacteremia versus 19/20 patients (95%) treated with comparators (vancomycin or linezolid). At end of treatment, 33/36 dalbavancin-treated patients (92%) achieved clinical success versus 18/23 patients (78%) treated with comparators.

Conclusions: All 39 patients with uncomplicated S. aureus bacteremia treated with dalbavancin (single- or two-dose regimen) and with follow-up blood cultures had clearance of their bloodstream infection. Clinical response rates were similar to daily comparator therapy for 10-14 days.

Trial registration: DISCOVER 1, NCT01339091; DISCOVER 2, NCT01431339; DUR001-303, NCT02127970; VER001-9; VER001-4, NCT00057369.

Keywords: Acute bacterial skin and skin structures infections; Bacteremia; Dalbavancin; Gram-positive.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Serum concentration of dalbavancin 1500 mg after intravenous administration as a 30-min infusion in a single-dose or two-dose regimen. Adapted with permission from Dunne M and Puttagunta S. Clearance of Staphylococcus aureus bacteremia in patients treated with dalbavancin. Presented at IDWeek, October 2–6, 2013; San Francisco, CA. http://www.idweek.org

References

    1. Economou NJ, Nahoum V, Weeks SD, et al. A carrier protein strategy yields the structure of dalbavancin. J Am Chem Soc. 2012;134:4637–4645. doi: 10.1021/ja208755j.
    1. Dalvance® (dalbavancin). Full Prescribing Information. Parsippany: Durata Therapeutics US Ltd.; 2021.
    1. Xydalba (dalbavancin). Summary of product characteristics. Amsterdam: Durata Therapeutics International BV; 2017.
    1. Dunne MW, Puttagunta S, Giordano P, et al. A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin Infect Dis. 2016;62:545–551. doi: 10.1093/cid/civ982.
    1. Boucher HW, Wilcox M, Talbot GH, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370:2169–2179. doi: 10.1056/NEJMoa1310480.
    1. Mendes RE, Castanheira M, Farrell DJ, et al. Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011–13) J Antimicrob Chemother. 2016;71:276–278. doi: 10.1093/jac/dkv303.
    1. Dorr MB, Jabes D, Cavaleri M, et al. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J Antimicrob Chemother. 2005;55:ii25–30. doi: 10.1093/jac/dki008.
    1. Dunne MW, Talbot GH, Boucher HW, Wilcox M, Puttagunta S. Safety of dalbavancin in the treatment of skin and skin structure infections: a pooled analysis of randomized, comparative studies. Drug Saf. 2016;39:147–157. doi: 10.1007/s40264-015-0374-9.
    1. Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens. Clin Infect Dis. 2005;40:374–380. doi: 10.1086/427283.
    1. Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2005;41:1407–1415. doi: 10.1086/497271.
    1. Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother. 2005;56:923–929. doi: 10.1093/jac/dki355.
    1. Fowler VG, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653–665. doi: 10.1056/NEJMoa053783.
    1. Wilcox MH, Tack KJ, Bouza E, et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis. 2009;48:203–212. doi: 10.1086/595686.
    1. Streifel AC, Sikka MK, Bowen CD, Lewis JS., 2nd Dalbavancin use in an academic medical centre and associated cost savings. Int J Antimicrob Agents. 2019;54:652–654. doi: 10.1016/j.ijantimicag.2019.08.007.
    1. Hidalgo-Tenorio C, Vinuesa D, Plata A, et al. DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by Gram-positive cocci. Ann Clin Microbiol Antimicrob. 2019;18:30. doi: 10.1186/s12941-019-0329-6.
    1. Hakim A, Braun H, Thornton D, Strymish J. Successful treatment of methicillin-sensitive Staphylococcus aureus tricuspid-valve endocarditis with dalbavancin as an outpatient in a person who injects drugs: a case report. Int J Infect Dis. 2020;91:202–205. doi: 10.1016/j.ijid.2019.12.008.
    1. Dinh A, Duran C, Pavese P, et al. French national cohort of first use of dalbavancin: a high proportion of off-label use. Int J Antimicrob Agents. 2019;54:668–672. doi: 10.1016/j.ijantimicag.2019.08.006.
    1. Tobudic S, Forstner C, Burgmann H, et al. Dalbavancin as primary and sequential treatment for Gram-positive infective endocarditis: 2-year experience at the General Hospital of Vienna. Clin Infect Dis. 2018;67:795–798. doi: 10.1093/cid/ciy279.
    1. Jones BM, Keedy C, Wynn M. Successful treatment of Enterococcus faecalis bacteremia with dalbavancin as an outpatient in an intravenous drug user. Int J Infect Dis. 2018;76:4–5. doi: 10.1016/j.ijid.2018.07.016.
    1. Bouza E, Valerio M, Soriano A, et al. Dalbavancin in the treatment of different Gram-positive infections: a real-life experience. Int J Antimicrob Agents. 2018;51:571–577. doi: 10.1016/j.ijantimicag.2017.11.008.
    1. Cho JC, Estrada SJ, Beltran AJ, Revuelta MP. Treatment of methicillin-sensitive Staphylococcus aureus bacteremia secondary to septic phlebitis using dalbavancin. J Clin Pharm Ther. 2015;40:604–606. doi: 10.1111/jcpt.12306.
    1. Bork JT, Heil EL, Berry S, et al. Dalbavancin use in vulnerable patients receiving outpatient parenteral antibiotic therapy for invasive Gram-positive infections. Infect Dis Ther. 2019;8:171–184. doi: 10.1007/s40121-019-0247-0.
    1. Ciccullo A, Giuliano G, Segala FV, et al. Dalbavancin as a second-line treatment in methicillin-resistant Staphylococcus aureus prosthetic vascular graft infection. Infection. 2020;48:309–310. doi: 10.1007/s15010-019-01379-2.
    1. Morrisette T, Miller MA, Montague BT, et al. Long-acting lipoglycopeptides: "lineless antibiotics" for serious infections in persons who use drugs. Open Forum Infect Dis. 2019;6:ofz274. doi: 10.1093/ofid/ofz274.
    1. Bryson-Cahn C, Beieler AM, Chan JD, Harrington RD, Dhanireddy S. Dalbavancin as secondary therapy for serious Staphylococcus aureus infections in a vulnerable patient population. Open Forum Infect Dis. 2019 doi: 10.1093/ofid/ofz028.
    1. Wunsch S, Krause R, Valentin T, et al. Multicenter clinical experience of real life dalbavancin use in Gram-positive infections. Int J Infect Dis. 2019;81:210–214. doi: 10.1016/j.ijid.2019.02.013.
    1. Antibacterial Resistance Leadership Group. DOTS: Dalbavancin as an option for treatment of S. aureus bacteremia. National Institute of Allergy and Infectious Diseases. 2021. . Accessed 15 Feb 2021.
    1. US Department of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry. Acute bacterial skin and skin structure infections: developing drugs for treatment. 2021. . Accessed 15 Feb 2021.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj